Voya Emerging Markets High Dividend Equity Fund (IHD)
Chart Events
Performance Outlook
| Previous Close | 5.70 |
| Open | 5.75 |
| Bid | 3.30 x 800 |
| Ask | 6.83 x 1000 |
| Day's Range | 5.80 - 5.85 |
| 52 Week Range | 5.60 - 8.68 |
| Volume | |
| Avg. Volume | 72,180 |
| Market Cap | 109.671M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.72 (12.48%) |
| Ex-Dividend Date | Apr 02, 2018 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for IHD
Related Research
- Voya Emerging Markets High IncoSEIC: Lowering target price to $60.00SEI INVESTMENTS COMPANY has an Investment Rating of HOLD; a target price of $60.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat4 months agoArgus Research
- Business Wire
Voya Equity Closed End Funds Declare Distributions
SCOTTSDALE, Ariz., June 15, 2022--Voya Investment Management, the asset management business of Voya Financial, Inc. (NYSE: VOYA), announced today the distributions on the common shares of three of its closed-end funds (each a "Fund" and collectively, the "Funds").
- GlobeNewswire
Vaxart Appoints Edward Berg as Senior Vice President and General Counsel
Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced the appointment of Edward B. Berg as the Company's first in-house General Counsel, effective today. Mr. Berg has practiced law for more than 30 years and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals and life sciences. He joins Vaxart from BioMarin Pharmaceutic
- GlobeNewswire
Vaxart Announces Acquisition of Second GMP Manufacturing Facility
Purchase expected to give Vaxart greater control over manufacturing schedulesSOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) has entered into an agreement with Kindred Bioscience, Inc. (“KindredBio”) for the purchase of KindredBio’s manufacturing equipment and sublease of its GMP (Good Manufacturing Practices) manufacturing facility in Burlingame, California, giving Vaxart control of its second GMP manufacturing facility. The transaction closed Tuesday,
